Key Takeaways Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates.The medical device maker's ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific’s portfolio of products includes treatments for kidney ... bladder and other conditions would complement its own urology business. The two companies said in a regulatory ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific (BSX – Research Report). The ...

Canaccord Genuity analyst William Plovanic has maintained their bullish stance on BSX stock, giving a Buy rating today. William Plovanic has ...

Boston Scientific exceeded Q3 expectations with $4.21 billion revenue and $0.63 EPS. Cardiovascular sales rose 25%, and 2024 ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral ... Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed.